‹ HRMY latest research

HRMY (Harmony Biosciences Holdings, I): every AI call and what happened next

TradeFlare's AI research teams analysed HRMY on 8 market nights between July 15, 2026 and October 2, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.

8 calls 7 BUY · 1 HOLD · 0 SELL BUY calls up after 20 trading days: 5 of 6
DateVerdictPriceTarget / stop5 days later20 days laterWhy (that night)
October 2, 2026 BUY $39.57 $45.50 / $33.63 +1.6% not yet
The fundamental strength and positive sentiment suggest a medium-term upward trend, but technicals and risk warrant a cautious approach.
September 29, 2026 HOLD $40.01 — / — +0.2% not yet
The current market and technical setup do not warrant a buy, despite positive fundamentals.
September 3, 2026 BUY $42.86 $47.15 / $36.43 -0.8% -5.3%
The stock is breaking out to new highs with strong fundamental support, suggesting a sustained move.
July 28, 2026 BUY $36.01 — / — +8.4% +8.9%
Continued strong revenue growth for WAKIX.
July 21, 2026 BUY $33.50 $36.85 / $30.15 -2.9% +5.4%
The fundamental strength and potential for a mean-reversion bounce suggest a medium-term opportunity.
July 20, 2026 BUY $33.77 $37.15 / $30.39 +7.5% +13.8%
The scanner trigger is an RSI pullback, suggesting a short-term mean-reversion opportunity.
July 17, 2026 BUY $33.53 $36.30 / $28.05 +4.6% +12.9%
The fundamental strength and positive news suggest a medium-term upward trend.
July 15, 2026 BUY $34.81 $38.29 / $31.33 -0.1% +13.9%
The fundamental and sentiment tailwinds suggest a medium-term upward trend, while the technical setup offers a short-term entry point.

Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.